Amundi
ROIV icon

Amundi’s Roivant Sciences ROIV Stock Holding History

Amundi’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.3M Sell
997,226
-483,744
-33% -$14.3M 0.01% 680
2026
Q1 		$41M Buy
1,480,970
+437,506
+42% +$11.2M 0.01% 633
2025
Q4 		$22.6M Buy
1,043,464
+1,011,048
+3,119% +$19.9M 0.01% 788
2025
Q3 		$527K Sell
32,416
-372,020
-92% -$4.61M ﹤0.01% 1310
2025
Q2 		$4.44M Buy
404,436
+5,707
+1% +$61.9K ﹤0.01% 946
2025
Q1 		$3.99M Buy
398,729
+61,214
+18% +$662K ﹤0.01% 1011
2024
Q4 		$3.72M Buy
337,515
+44,019
+15% +$520K ﹤0.01% 1045
2024
Q3 		$3.31M Buy
293,496
+293,219
+105,855% +$3.34M ﹤0.01% 1060
2024
Q2 		$2.9K Sell
277
-231,294
-100% -$2.53M ﹤0.01% 1899
2024
Q1 		$2.4M Buy
231,571
+67,188
+41% +$724K ﹤0.01% 1113
2023
Q4 		$1.87M Sell
164,383
-195,354
-54% -$1.9M ﹤0.01% 1215
2023
Q3 		$3.63M Buy
359,737
+122,985
+52% +$1.39M ﹤0.01% 1043
2023
Q2 		$2.31M Buy
236,752
+211,391
+834% +$1.89M ﹤0.01% 1133
2023
Q1 		$180K Buy
25,361
+2,433
+11% +$20K ﹤0.01% 1595
2022
Q4 		$222K Buy
+22,928
New +$128K ﹤0.01% 1502

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Amundi's ROIV Position: Q2 2026 in Review

Amundi reduced its Roivant Sciences (ROIV) stake by 33% in Q2 2026, selling an estimated $14.3M and leaving 997,226 shares worth $35.3M. The position accounts for 0.01% of the portfolio, ranked #680.

Amundi first reported a position in ROIV in Q4 2022 and has held it in 15 quarters since. The position peaked at $41M in Q1 2026. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Amundi held 997,226 shares of Roivant Sciences worth $35.3M as of Q2 2026.
  • Amundi sold 483,744 Roivant Sciences shares in Q2 2026, an estimated $14.3M.
  • Roivant Sciences made up 0.01% of Amundi's portfolio in Q2 2026, its #680 holding.
  • Amundi first reported a position in Roivant Sciences in Q4 2022 and has held it in 15 quarters since.
  • Amundi's Roivant Sciences position peaked at $41M in Q1 2026.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.